Journal
JOURNAL OF IMMUNOLOGY
Volume 190, Issue 12, Pages 6239-6249Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1300448
Keywords
-
Categories
Funding
- Kakenhi [24390210, 22390166, 23790185, 23701043, 23791584]
- Ministry of Education, Culture, Sports, Science and Technology of Japan
- Mitsubishi Pharma Research Foundation
- Children's Cancer Association of Japan
- Intelligent Cosmos Academic Foundation
- Platform for Drug Discovery, Informatics, and Structural Life Science
- Regional Innovation Strategy Support Program
- Grants-in-Aid for Scientific Research [22390166, 23701043, 23791584, 23790185, 24390210] Funding Source: KAKEN
Ask authors/readers for more resources
Podoplanin (Aggrus), which is a type I transmembrane sialomucin-like glycoprotein, is highly expressed in malignant pleural mesothelioma (MPM). We previously reported the generation of a rat anti-human podoplanin Ab, NZ-1, which inhibited podoplanin-induced platelet aggregation and hematogenous metastasis. In this study, we examined the antitumor effector functions of NZ-1 and NZ-8, a novel rat-human chimeric Ab generated from NZ-1 including Ab-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity against MPM in vitro and in vivo. Immunostaining with NZ-1 showed the expression of podoplanin in 73% (11 out of 15) of MPM cell lines and 92% (33 out of 36) of malignant mesothelioma tissues. NZ-1 could induce potent ADCC against podoplanin-positive MPM cells mediated by rat NK (CD161a(+)) cells, but not murine splenocytes or human mononuclear cells. Treatment with NZ-1 significantly reduced the growth of s.c. established tumors of MPM cells (ACC-MESO-4 or podoplanin-transfected MSTO-211H) in SCID mice, only when NZ-1 was administered with rat NK cells. In in vivo imaging, NZ-1 efficiently accumulated to xenograft of MPM, and its accumulation continued for 3 wk after systemic administration. Furthermore, NZ-8 preferentially recognized podoplanin expressing in MPM, but not in normal tissues. NZ-8 could induce higher ADCC mediated by human NK cells and complement-dependent cytotoxicity as compared with NZ-1. Treatment with NZ-8 and human NK cells significantly inhibited the growth of MPM cells in vivo. These results strongly suggest that targeting therapy to podoplanin with therapeutic Abs (i.e., NZ-8) derived from NZ-1 might be useful as a novel immunotherapy against MPM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available